Detection of Axillary Lymph Node Metastases and Extra-Axillary Metastases With FDG PET/CT in Breast Cancer Patients Scheduled for Neoadjuvant Chemotherapy

2013 ◽  
Vol 3 (2) ◽  
pp. S24-S25
Author(s):  
G.M. Jacobson ◽  
G. Marano ◽  
H. Hazard ◽  
J. Abraham
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Axillary Metastases ◽  
Axillary Lymph Node Metastases ◽  
Pet Ct ◽  
Node Metastases ◽  
Fdg Pet Ct

scholarly journals Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients

2010 ◽  
Vol 37 (6) ◽  
pp. 1069-1076 ◽  
Author(s):  
Marieke E. Straver ◽  
Tjeerd S. Aukema ◽  
Renato A. Valdes Olmos ◽  
Emiel J. T. Rutgers ◽  
Kenneth G. A. Gilhuijs ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Axillary Lymph Node Metastases ◽  
Pet Ct ◽  
Node Metastases ◽  
Fdg Pet Ct

Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients

2012 ◽  
Vol 53 (5) ◽  
pp. 518-523 ◽  
Author(s):  
Steffen Hahn ◽  
Jennifer Hecktor ◽  
Florian Grabellus ◽  
Verena Hartung ◽  
Thorsten Pöppel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Axillary Lymph Node Metastases ◽  
Pet Ct ◽  
Node Metastases ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Time Point

Lymph Node to Primary Tumor SUV Ratio by 18F-FDG PET/CT and the Prediction of Axillary Lymph Node Metastases in Breast Cancer

2014 ◽  
Vol 39 (4) ◽  
pp. e249-e253 ◽  
Author(s):  
Jihyun Park ◽  
Byung Hyun Byun ◽  
Woo Chul Noh ◽  
Seung Sook Lee ◽  
Hyun-Ah Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Primary Tumor ◽  
Axillary Lymph ◽  
Axillary Lymph Node Metastases ◽  
Pet Ct ◽  
Node Metastases ◽  
18F Fdg ◽  
Fdg Pet Ct

Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy

2011 ◽  
Vol 50 (01) ◽  
pp. 33-38 ◽  
Author(s):  
R. Reitsamer ◽  
J. Holzmannhofer ◽  
G. Rendl ◽  
C. Pirich ◽  
C. Kronberger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Lymphatic Mapping ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

SummaryThe aim of this study was to evaluate the diagnostic value of lymphatic mapping by lymphoscintigraphy in breast cancer patients undergoing neoadjuvant chemotherapy (NCTX). We assessed the association between clinicopathological factors and nonvisualized sentinel nodes during preoperative lymphoscintigraphy. As secondary aims, we analyzed whether post NCTX axillary ultrasonography and fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography (F18-FDG-PET/CT) might be useful for staging in case of nonvisualized sentinel nodes. Patients, methods: 61 patients with newly diagnosed, invasive breast cancer potentially eligible for NCTX were included in this substudy of a prospective trial on the monitoring of NCTX with 18F-FDG PET/CT. In all patients, lymphoscintigraphy was performed prior to sentinel lymph node biopsy (SLNB). 42 patients received neoadjuvant chemotherapy. 19 patients did not receive NCTX. After SLNB, mastectomy or lumpectomy (breast-conserving surgery) combined with level I and II axillary lymph node dissection were performed. Cases of nonvisualized sentinel nodes were analyzed with respect to tumour and patient characteristics and the results of ultrasonography and 18F-FDG-PET/CT before and after NCTX. Results: Lymphoscintigram successfully identified at least one sN in 55 patients (i.e. identification rate of 90%). The risk of failure to identify the sN was associated statistically with a positive clinical nodal status prior to NCTX (p = 0.021). There was no statistical difference between patients with visualized and nonvisualized sN with respect to age, tumour grade, tumour size, pathological lymph node status or tumour histology. In patients without NCTX the sN identification rate was 100% versus 86% in patients with NCTX (n.s.). The FNR of patients with NCTX was 9.1%. Post NCTX axillary ultrasonography or FDG-PET/CT did not provide accurate information about the lymph node status in case of failing lymphatic mapping. Conclusion: On the basis of our findings, SLNB can not yet be recommended as a reliable staging method in breast cancer patients undergoing neoadjuvant chemotherapy. Patients with clinically positive axillary lymph nodes have a higher chance of unsuccessful lymphatic mapping by lymphoscintigraphy. Performing SLNB before NCTX in clinically node-negative patients may identify the subset of patients in whom axillary lymph node dissection can be omitted. Post NCTX axillary ultrasonography and 18F-FDG-PET/CT can not be suggested as valid axillary staging methods in case of a failed lymphatic mapping.

Are Breast Cancer Nomograms Still Valid to Predict the Need for Axillary Dissection?

Oncology ◽  
2021 ◽  
pp. 1-5
Author(s):  
Vilma Madekivi ◽  
Antti Karlsson ◽  
Pia Boström ◽  
Eeva Salminen
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Axillary Dissection ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Axillary Lymph Node Metastases ◽  
Node Negative ◽  
Node Metastases ◽  
External Population

Background: Nomograms can help in estimating the nodal status among clinically node-negative patients. Yet their validity in external cohorts over time is unknown. If the nodal stage can be estimated preoperatively, the need for axillary dissection can be decided. Objectives: The aim of this study was to validate three existing nomograms predicting 4 or more axillary lymph node metastases. Method: The risk for ≥4 lymph node metastases was calculated for n = 529 eligible breast cancer patients using the nomograms of Chagpar et al. [Ann Surg Oncol. 2007;14:670–7], Katz et al. [J Clin Oncol. 2008;26(13):2093–8], and Meretoja et al. [Breast Cancer Res Treat. 2013;138(3):817–27]. Discrimination and calibration were calculated for each nomogram to determine their validity. Results: In this cohort, the AUC values for the Chagpar, Katz, and Meretoja models were 0.79 (95% CI 0.74–0.83), 0.87 (95% CI 0.83–0.91), and 0.82 (95% CI 0.76–0.86), respectively, showing good discrimination between patients with and without high nodal burdens. Conclusion: This study presents support for the use of older breast cancer nomograms and confirms their current validity in an external population.

Sign in / Sign up

Export Citation Format

Share Document